ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

Vinblastine for injection
Breast cancer
Gynecologic cancers
Kaposi's sarcoma
Leukemias, lymphomas, and other hematologic cancers
Prostate and other male cancers
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

Vinblastine for injection Rx

Generic Name and Formulations:
Vinblastine (as sulfate) 10mg/vial; lyophilized pwd for IV inj or infusion after reconstitution.

Company:
Bedford Laboratories

Therapeutic Use:

Indications for Vinblastine for injection:

Less frequently responsive: breast cancer, unresponsive to endocrine surgery and hormonal therapy.

Adult:

See literature. Give by IV once weekly. 1st dose: 3.7mg/m2 as a single dose, continue to increase dose by increments (2nd dose: 5.5mg/m2, 3rd dose: 7.4mg/m2, 4th dose: 9.25mg/m2, 5th dose: 11.1mg/m2, max dose: 18.5mg/m2) until WBC 3,000cells/mm3 reached, stop at this dose, then administer a dose one increment smaller at weekly intervals for maintenance. Usual weekly dosage: 5.5–7.4mg/m2. Do not give the next dose, even if 7 days have elapsed, unless WBC ≥4,000cells/mm3. If oncolytic effect occurs before leukopenia, do not increase the size of subsequent doses. Hepatic impairment: reduce dose by 50% if serum bilirubin >3mg/100mL.

Children:

Not recommended.

Contraindications:

Significant granulocytopenia (unless result of disease being treated). Bacterial infections (treat first).

Warnings/Precautions:

For IV use only; fatal if given intrathecally. Hepatic impairment. Avoid in elderly with cachexia or ulcerated skin; or in patients with malignant-cell infiltration of the bone marrow. Pre-existing pulmonary dysfunction. Progressive dyspnea requiring chronic therapy (do not re-administer). Ischemic cardiac disease. Bone marrow suppression; monitor WBC before and during treatment. Avoid contamination of the eyes or injecting into an extremity with poor circulation (thrombosis possible). Avoid extravasation. Pregnancy (Cat.D), nursing mothers: not recommended.

Interactions:

May be potentiated by CYP3A inhibitors (eg, erythromycin). Antagonizes phenytoin.

See Also:

Vinblastine injection

Pharmacological Class:

Antimicrotubule agent.

Adverse Reactions:

Leukopenia, alopecia, GI upset, paresthesias, malaise, pain; dyspnea, severe bronchospasm.

How Supplied:

Pwd—10; Soln—1

Indications for Vinblastine for injection:

Less frequently responsive: choriocarcinoma resistant to other chemotherapy.

Adult:

See literature. Give by IV once weekly. 1st dose: 3.7mg/m2 as a single dose, continue to increase dose by increments (2nd dose: 5.5mg/m2, 3rd dose: 7.4mg/m2, 4th dose: 9.25mg/m2, 5th dose: 11.1mg/m2, max dose: 18.5mg/m2) until WBC 3,000cells/mm3 reached, stop at this dose, then administer a dose one increment smaller at weekly intervals for maintenance. Usual weekly dosage: 5.5–7.4mg/m2. Do not give the next dose, even if 7 days have elapsed, unless WBC ≥4,000cells/mm3. If oncolytic effect occurs before leukopenia, do not increase the size of subsequent doses. Hepatic impairment: reduce dose by 50% if serum bilirubin >3mg/100mL.

Children:

Not recommended.

Contraindications:

Significant granulocytopenia (unless result of disease being treated). Bacterial infections (treat first).

Warnings/Precautions:

For IV use only; fatal if given intrathecally. Hepatic impairment. Avoid in elderly with cachexia or ulcerated skin; or in patients with malignant-cell infiltration of the bone marrow. Pre-existing pulmonary dysfunction. Progressive dyspnea requiring chronic therapy (do not re-administer). Ischemic cardiac disease. Bone marrow suppression; monitor WBC before and during treatment. Avoid contamination of the eyes or injecting into an extremity with poor circulation (thrombosis possible). Avoid extravasation. Pregnancy (Cat.D), nursing mothers: not recommended.

Interactions:

May be potentiated by CYP3A inhibitors (eg, erythromycin). Antagonizes phenytoin.

See Also:

Vinblastine injection

Pharmacological Class:

Antimicrotubule agent.

Adverse Reactions:

Leukopenia, alopecia, GI upset, paresthesias, malaise, pain; dyspnea, severe bronchospasm.

How Supplied:

Pwd—10; Soln—1

Indications for Vinblastine for injection:

Frequently responsive: palliative treatment of Kaposi's sarcoma.

Adult:

See literature. Give by IV once weekly. 1st dose: 3.7mg/m2 as a single dose, continue to increase dose by increments (2nd dose: 5.5mg/m2, 3rd dose: 7.4mg/m2, 4th dose: 9.25mg/m2, 5th dose: 11.1mg/m2, max dose: 18.5mg/m2) until WBC 3,000cells/mm3 reached, stop at this dose, then administer a dose one increment smaller at weekly intervals for maintenance. Usual weekly dosage: 5.5–7.4mg/m2. Do not give the next dose, even if 7 days have elapsed, unless WBC ≥4,000cells/mm3. If oncolytic effect occurs before leukopenia, do not increase the size of subsequent doses. Hepatic impairment: reduce dose by 50% if serum bilirubin >3mg/100mL.

Children:

Not recommended.

Contraindications:

Significant granulocytopenia (unless result of disease being treated). Bacterial infections (treat first).

Warnings/Precautions:

For IV use only; fatal if given intrathecally. Hepatic impairment. Avoid in elderly with cachexia or ulcerated skin; or in patients with malignant-cell infiltration of the bone marrow. Pre-existing pulmonary dysfunction. Progressive dyspnea requiring chronic therapy (do not re-administer). Ischemic cardiac disease. Bone marrow suppression; monitor WBC before and during treatment. Avoid contamination of the eyes or injecting into an extremity with poor circulation (thrombosis possible). Avoid extravasation. Pregnancy (Cat.D), nursing mothers: not recommended.

Interactions:

May be potentiated by CYP3A inhibitors (eg, erythromycin). Antagonizes phenytoin.

See Also:

Vinblastine injection

Pharmacological Class:

Antimicrotubule agent.

Adverse Reactions:

Leukopenia, alopecia, GI upset, paresthesias, malaise, pain; dyspnea, severe bronchospasm.

How Supplied:

Pwd—10; Soln—1

Indications for Vinblastine for injection:

Frequently responsive: palliative treatment of generalized Hodgkin's disease, lymphocytic lymphoma, histiocytic lymphoma, mycosis fungoides.

Adult:

See literature. Give by IV once weekly. 1st dose: 3.7mg/m2 as a single dose, continue to increase dose by increments (2nd dose: 5.5mg/m2, 3rd dose: 7.4mg/m2, 4th dose: 9.25mg/m2, 5th dose: 11.1mg/m2, max dose: 18.5mg/m2) until WBC 3,000cells/mm3 reached, stop at this dose, then administer a dose one increment smaller at weekly intervals for maintenance. Usual weekly dosage: 5.5–7.4mg/m2. Do not give the next dose, even if 7 days have elapsed, unless WBC ≥4,000cells/mm3. If oncolytic effect occurs before leukopenia, do not increase the size of subsequent doses. Hepatic impairment: reduce dose by 50% if serum bilirubin >3mg/100mL.

Children:

See literature. IV use only. Hodgkin's disease: initially 6mg/m2. Adjust dose according to hematologic tolerance.

Contraindications:

Significant granulocytopenia (unless result of disease being treated). Bacterial infections (treat first).

Warnings/Precautions:

For IV use only; fatal if given intrathecally. Hepatic impairment. Avoid in elderly with cachexia or ulcerated skin; or in patients with malignant-cell infiltration of the bone marrow. Pre-existing pulmonary dysfunction. Progressive dyspnea requiring chronic therapy (do not re-administer). Ischemic cardiac disease. Bone marrow suppression; monitor WBC before and during treatment. Avoid contamination of the eyes or injecting into an extremity with poor circulation (thrombosis possible). Avoid extravasation. Pregnancy (Cat.D), nursing mothers: not recommended.

Interactions:

May be potentiated by CYP3A inhibitors (eg, erythromycin). Antagonizes phenytoin.

See Also:

Vinblastine injection

Pharmacological Class:

Antimicrotubule agent.

Adverse Reactions:

Leukopenia, alopecia, GI upset, paresthesias, malaise, pain; dyspnea, severe bronchospasm.

How Supplied:

Pwd—10; Soln—1

Indications for Vinblastine for injection:

Frequently responsive: palliative treatment of advanced carcinoma of the testis.

Adult:

See literature. Give by IV once weekly. 1st dose: 3.7mg/m2 as a single dose, continue to increase dose by increments (2nd dose: 5.5mg/m2, 3rd dose: 7.4mg/m2, 4th dose: 9.25mg/m2, 5th dose: 11.1mg/m2, max dose: 18.5mg/m2) until WBC 3,000cells/mm3 reached, stop at this dose, then administer a dose one increment smaller at weekly intervals for maintenance. Usual weekly dosage: 5.5–7.4mg/m2. Do not give the next dose, even if 7 days have elapsed, unless WBC ≥4,000cells/mm3. If oncolytic effect occurs before leukopenia, do not increase the size of subsequent doses. Hepatic impairment: reduce dose by 50% if serum bilirubin >3mg/100mL.

Children:

See literature. IV use only. Testicular germ cell carcinomas: initially 3mg/m2. Adjust dose according to hematologic tolerance.

Contraindications:

Significant granulocytopenia (unless result of disease being treated). Bacterial infections (treat first).

Warnings/Precautions:

For IV use only; fatal if given intrathecally. Hepatic impairment. Avoid in elderly with cachexia or ulcerated skin; or in patients with malignant-cell infiltration of the bone marrow. Pre-existing pulmonary dysfunction. Progressive dyspnea requiring chronic therapy (do not re-administer). Ischemic cardiac disease. Bone marrow suppression; monitor WBC before and during treatment. Avoid contamination of the eyes or injecting into an extremity with poor circulation (thrombosis possible). Avoid extravasation. Pregnancy (Cat.D), nursing mothers: not recommended.

Interactions:

May be potentiated by CYP3A inhibitors (eg, erythromycin). Antagonizes phenytoin.

See Also:

Vinblastine injection

Pharmacological Class:

Antimicrotubule agent.

Adverse Reactions:

Leukopenia, alopecia, GI upset, paresthesias, malaise, pain; dyspnea, severe bronchospasm.

How Supplied:

Pwd—10; Soln—1

Sign Up for Free e-newsletters